We evolved muscarinic receptors in yeast to generate a family of G protein-coupled receptors (GPCRs) that are activated solely by a pharmacologically inert drug-like and bioavailable compound (clozapine-N-oxide). Subsequent screening in human cell lines facilitated the creation of a family of muscarinic acetylcholine GPCRs suitable for in vitro and in situ studies. We subsequently created lines of telomerase-immortalized human pulmonary artery smooth muscle cells stably expressing all five family members and found that each one faithfully recapitulated the signaling phenotype of the parent receptor. We also expressed a G i-coupled designer receptor in hippocampal neurons (hM 4D) and demonstrated its ability to induce membrane hyperpolarization and neuronal silencing. We have thus devised a facile approach for designing families of GPCRs with engineered ligand specificities. Such reverse-engineered GPCRs will prove to be powerful tools for selectively modulating signal-transduction pathways in vitro and in vivo.
B
ecause of the assorted cellular responses directed by them, their number, and the ease of which they are pharmacologically screened, the superfamily of G protein-coupled receptors (GPCRs) is one of the most therapeutically important targets in the proteome (1) . However, the potential of this family is restricted by our ability to assess their function, which currently involves transgenic, knockout, and/or in vivo studies with selective drugs. Genetic studies are frequently limited to loss-of-function phenotypes, whereas nonselectiveness of a drug often interferes with interpretation of pharmacological studies. Knowledge of the roles of the individual family members is being bolstered by the ongoing creation of knockout mice for many GPCRs. Selective activation of individual GPCR subtypes in a defined tissue, in either a knockout or wild-type animal, is currently problematic but, if possible, would serve to complement present findings by providing novel insights into disease states resulting from overstimulation of certain signaling pathways.
One approach to this problem has been to rationally modify receptors to favor synthetic over natural substrate/ligand recognition, and subsequently, these mutant proteins have been used as bio-tools to study protein function in complex biological environments (2, 3) . At the forefront of such modified GPCRs is Ro1, a G i/o -coupled opioid receptor activated by a synthetic but not a native ligand, which has been conditionally expressed in transgenic mice to study cardiac function after its selective activation (4) . Such mutant receptors, like Ro1, have been classified as receptors activated solely by synthetic ligands (RASSLs), because they are activated by synthetic ligands but not by their endogenous ligands (5) . RASSLs, as in the case of Ro1, have been demonstrated to be valuable tools (4, 6) ; however, because the synthetic ligand frequently has high affinity and/or potency at the native receptor (5, 7, 8) , this potentially limits their usefulness in vivo, at least in tissues with a wild-type receptor present. In this context, we sought to develop designer receptors exclusively activated by a designer drug (DREADD), or simply ''designer'' receptors, which represent receptors that are activated solely by a synthetic ligand(s) possessing minimal or no biologic activity.
In this study, we present a directed molecular evolution approach, which facilitated the creation of a family of muscarinic receptors that is potently activated by the pharmacologically inert compound clozapine-N-oxide (CNO) but not by its native ligand acetylcholine (ACh). We further demonstrate that such designer muscarinic receptors are active in a variety of native and artificial cellular contexts. We thus provide a validated and unbiased approach for generating GPCRs with defined ligand specificities and for proof of concept have created a family of muscarinic ACh receptor (mAChR) DREADDs having promise as unique biological tools to study either receptor-specific functions [e.g., , human mAChR DREADD subtype 3 (hM 3 ) vs. hM 1 ] or general downstream signaling (e.g., G q/11 vs. G i/o ) emanating from the activated GPCR.
Results

Directed Molecular Evolution of Rat M3 Receptor in Yeast.
We set out to develop an M 3 DREADD that was responsive to a synthetic ligand of choice by using a directed molecular evolution approach. CNO was selected as the synthetic ligand because: (i) its parent compound, clozapine, has high affinity to M 3 receptors and, therefore, we predicted few mutations would be required to permit CNO to be a potent agonist; (ii) CNO is highly bioavailable in rodents and humans (9, 10) ; and (iii) importantly, CNO is a pharmacologically inert molecule lacking appreciable (Ͻ1 M) affinity for receptors [ref. 11 and supporting information (SI) Fig.  6 ]. For initial studies, a modified rat M 3 receptor containing a sizable deletion in its third intracellular loop [(i3); rM 3 ⌬i3] was used (SI Fig. 7 ). The rat M 3 ⌬i3 receptor has been previously demonstrated to be functionally expressed in Saccharomyces cerevisiae genetically modified to enable ligand activation of heterologously expressed mammalian GPCRs to engage the pheromone signaling pathway to promote growth on selective medium (12) .
By means of random mutagenesis, we created a large library of Table 1 ). This was a promising finding, because we anticipated that clones selected to be activated by clozapine may be prone to CNO activation as well. A subset of clones were selected to be remutated to manufacture a second-generation library to select for mutants activated by 1 M CNO (SI Table 1 and SI Materials and Methods). The second-generation rM 3 ⌬i3 receptor mutants were efficaciously activated by CNO with a broad range of potencies (35-5,000 nM), which invariably was accompanied by a Ϸ100-fold increase in clozapine vs. CNO potency ( Fig. 1 and SI Table  1 ). Again all mutants, with a single exception, had Ն1,000-fold reduction in ACh potency (SI Table 1 ).
A final library was constructed by using a subset of the second-generation CNO-responsive rM 3 ⌬i3 receptor mutants as the mutagenesis template and screened with Ϸ5 nM CNO to select for potently activated mutants (SI Table 1 and SI Materials and Methods). Two clones were isolated that were activated by CNO and clozapine with potencies of Ͻ10 nM and Ϸ0.1 nM, respectively ( Fig. 1 and SI Table 1 ).
Engineering an hM3 Receptor to Be Potently and Efficaciously Activated by CNO in Human Cells. Using the yeast-based screen, we were able to greatly enhance the pharmacological attributes of CNO at the M 3 receptor. However, the ultimate goal was to create a full-length M 3 receptor suitable for mammalian use. We next determined whether the mutants obtained by the yeast screen would be directly useful in human cells. In mammalian cells, activation of G q/11 -coupled receptors, like M 3 receptor, can be measured by the accumulation of inositol monophosphate (IP 1 ), a metabolite of inositol trisphosphate (IP 3 ) produced by phospholipase C ␤ catalyzed hydrolysis of phosphatidylinositol (PI).
CNO was essentially inactive at wild-type rM 3 ⌬i3 transiently expressed in HEK T cells, whereas selected mutant rM 3 ⌬i3 receptors displayed robust responses to CNO as well greatly diminished ACh potency ( Fig. 2A and SI Table 2 ). Because many of the mutants with the highest CNO potencies had high levels of constitutive activity ( Fig. 2 A and SI Table 2 ), we next screened a focused library of hM 3 receptor mutants in HEK T cells to generate a receptor that was potently activated by CNO with minimal constitutive activity.
We chose the Y149C 3.33 mutant as an initial template because, (i) the rM 3 ⌬i3 Y148 3.33 was the most consistently mutated residue to arise in the yeast screen, (ii) the Tyr 3.33 residue is known to be important in ligand binding of muscarinic ligands (13) (14) (15) , and (iii) preliminary experiments showed that mutation of Tyr-149 3.33 in hM 3 receptor to either Cys or His similarly increased CNO responsiveness without increasing basal activity, yet the Y149C mutant had Ϸ100-fold better reduction in ACh potency compared with Y149H when expressed in HEK T cells ( Fig. 2 and SI Table 2 ). Ultimately, we found the double mutant Y149C 3.33 /A239G
5.46 to be the best possible combination of mutations to generate a hM 3 DRE-ADD (hM 3 D) ( Fig. 2 and SI Table 2 ).
Characterization of hM3 DREADD in Immortalized Human Pulmonary
Artery Smooth Muscle Cells (hPASMC). Although smooth muscle cells endogenously express M 3 receptors (16), we found a particular human hPASMC line, devoid of endogenous muscarinic receptors, which would allowed us to investigate hM 3 D receptor function in a null but native environment. We were able to immortalize hPASMCs, as determined by propagating cells well past senescence, by the stable introduction of the gene encoding the human catalytic subunit of telomerase, hTERT (SI Fig. 8 ). When wild-type hM 3 receptors were stably expressed in immortalized hPASMCs, they faithfully elicited PI hydrolysis, Ca 2ϩ mobilization and ERK-1/2 phosphorylation (see below and SI Materials and Methods for assay description) after ACh treatment ( Fig. 3 and SI Tables 3-5) . Significantly, the hM 3 D receptor stably expressed in immortalized hPASMCs was potently (Ϸ20-30 nM) and efficaciously activated by CNO (Fig. 3 A and B and SI Tables 3 and 4 ). The hM 3 D was found to have a severe reduction (Ͼ40,000-fold) in ACh potency compared with the wild-type receptor ( Fig. 3 and SI Tables 3 and 4) .
Because some interactions between drug and receptor result in the onset of some but not all GPCR-related functions (17), we wanted to test whether hM 3 D receptors could stimulate distinct downstream pathways after CNO treatment. A common signaling event radiating from activated GPCRs is the downstream phosphorylation of the MAPK proteins, ERK-1/2, resulting from the association of the MAPK-␤-arrestin complex with the activated receptor (1). Treatment with 1 M ACh but not CNO resulted in an enhanced level of ERK-1/2 phosphorylation in hPASMCs expressing hM 3 receptors (Fig. 3C) . Conversely, hPASMCs expressing hM 3 D receptors responded only to CNO under the same conditions (Fig. 3D) (Fig. 4A and SI Tables 3 and 4) . Receptor activation remained sensitive, albeit with reduced potency, to the nonselective mACh receptor antagonists, atropine and (Ϯ)-quinuclidinyl benzilate, as monitored by Ca 2ϩ mobilization (SI Table 6 ). We found treatment of immortalized hPASMCs with pertussis toxin, an irreversible G i/o inhibitor, selectively abolished the Ca 2ϩ response in those cells expressing hM 2 and hM 4 compared with hM 1, 3, and 5 receptors (Fig. 4B and data not shown) . Additionally, treatment of CNO selectively reduces forskolin-stimulated cAMP formation in hPASMCs expressing hM 2 D receptors with a potency similar to that seen by Ca 2ϩ mobilization assays (SI Materials and Methods and SI Tables 4 and 7) . Therefore, hM 2 and hM 4 receptors retain their coupling properties when expressed in hPASMCs and presumably activate phospholipase C ␤ by G ␤ ␥ subunits (19) . We first verified that the hM 4 D receptor could modify GIRK currents in HEK cells transiently expressing GIRK1/2 subunits in combination with hM 4 D receptor. As a control, we found that 10 M CCh could induce currents in HEK cells transfected with GIRK1/2 subunits and wild-type hM 4 receptors, whereas as little to no current was found in cells treated with the same concentration of CNO (Fig. 5 A and B Upper) . As anticipated, CNO compared with CCh, which had no effect, selectively activated GIRK channels in HEK cells that hM 4 D receptors were coexpressed ( Fig. 5 A and B Lower) .
We next examined whether this behavior was recapitulated in cultured hippocampal neurons. When wild-type hM 4 receptors were transiently expressed in hippocampal neurons, we found that CCh, but not CNO, induced hyperpolarization ( Fig. 5 C and D  Upper) . Significantly, CNO treatment of culture hippocampal neurons transiently expressing hM 4 D receptor also resulted in neuronal hyperpolarization (Fig. 5 C and D Lower) . Expression of hM 4 D receptors in these neurons did not prevent CCh from modulating hyperpolarization through endogenous receptors (Fig. 5C and data not shown), suggesting that expression of hM 4 D does not impede native receptor function. Additionally, CNO can selectively prevent action potential firing in cultured hippocampal neurons expressing hM 4 D receptors (Fig. 5E ) without significantly altering resting membrane potential in untreated infected neurons (Fig. 5F ). These experiments clearly establish the unique ability of CNO to exclusively activate a cellular response in cells exogenously expressing hM 4 D receptors and demonstrate their utility as a tool for in vivo neuronal silencing.
Discussion
Here we demonstrate that directed molecular evolution can be used to engineer a GPCR to be potently and efficaciously activated by a synthetic ligand that is pharmacologically inert. We extend this approach to show that an entire family of GPCRs, in this case the human muscarinic receptor family, can be created to be activated by an inert ligand. We also show that the signal transduction pathways and novel pharmacologies are faithfully recapitulated in a variety of cellular contexts including smooth muscle cells and hippocampal neurons. We suggest that at least one of these designer receptors, hM 4 D, will prove useful for neuronal silencing in vitro and in vivo. Using this general approach, it should be possible to eventually evolve GPCRs to bind any arbitrary drug-like small molecule by essentially designing the ''lock'' (GPCR) to fit the ''key'' (the ligand).
There are a number of technical considerations that should be borne in mind when embarking on a campaign to reverse engineer a GPCR. We found, in general, that most of the key ''transforming'' residues were found in the initial screen and, compared with those mutants found in later screens, more of these mutants had unchanged basal activity when expressed in human cells. Therefore, it is advisable to screen a large initial library, which is likely to have the highest impact in unearthing important and easily identifiable residues, as well as counter screen promising mutants in mammalian cells early on to reduce the risk of evolving constitutively active receptors. A distinct advantage to directed evolution by using randomized libraries is that is unbiased. However, the screen can be significantly enhanced with prior knowledge of residue importance. Not surprisingly, four residues (Y 3.33 , T 5.42 , W 6.48 , and Y 6.51 ) involved in binding to ACh and other mAChR ligands (13, 21) were mutated in our screen, illustrating that special attention should be given to these residues or local helical regions. Intriguingly, this lends evidence to the notion that clozapine-related ligands, such as clozapine, CNO, and olanzapine (data not shown), which readily activate the hM 3 D receptor, may either bind distinctly within the ACh orthosteric site or, as previously suggested, are allosteric ligands (18) . Similarly, it is potentially worthwhile to perform saturating mutagenesis at residue ''hot spots'' to optimize functionality, because we found multiple substitutions at one residue (e.g., Y148C/H/N 3.33 ) enhanced rM 3 ⌬i3 receptor activation by clozapine/ CNO in yeast and considering most single-nucleotide mutations within a codon will not change the translated amino acid to all of the other possible amino acids. For example, in our initial library, if all possible single-nucleotide mutations were introduced within the Y148 codon, only 7 of 19 possible amino acid substitutions would have been achieved. In this way, subsequent libraries would be seeded with an optimized receptor while avoiding propagation of unimportant secondary mutations.
The first reported receptor that can be considered a DREADD is a ␤ 2 -adrenergic receptor rationally mutated at the highly conserved residue D113S 3.32 . This mutant had a severe reduction in both potency and efficacy to catecholamine agonists but instead was fully activated, albeit with low potency (Ͼ40 M), by compounds foreign to the wild-type receptor (22) . More recently, rational mutation of F435A 6.55 in the histamine H 1 receptor (23) and D100A 3.32 of the 5-HT 4 receptor (8) [the first G q/11 and G s -coupled receptors activated solely by synthetic ligands (RASSLs), respectively] enhanced the potency for synthetic ligands and reduced affinity and potency for their native ligands, although not nearly to same extent as the mACh DREADDs described here.
Here, guided by mutations arising from directed molecular evolution in yeast, we discovered Y 3.33 C and A 5.46 G mutations to be sufficient to generate a human hM 3 DREADD that responded potently, efficaciously, and selectively to CNO vs. ACh by PI hydrolysis, Ca 2ϩ mobilization, and ERK-1/2 phosphorylation in a physiologically relevant background. Fortuitously, mutations at these same two conserved residues effectively switched the responsiveness of all other human mAChR family members so that CNO selectively activated them in two independent cellular settings by using a variety of signaling readouts. Interestingly, this dramatic enhancement of functional activation is accompanied by a minimal (Ͻ5-fold) increase in CNO affinity, which remains to be explored (not shown).
Knockout of individual or combinations of mACh receptors in mice has given enormous insight into function and possible pathophysiologies resulting to disruption of these receptors (16) . However, these studies provide limited insight into what role either acute or chronic receptor overstimulation plays in disease states. For example, studies have shown that M 1 and M 4 knockout mice have increased locomotor activity and modified dopamine levels and/or release (24) (25) (26) ; however, it is difficult to decipher whether and which receptors exert a tonic check for movement or whether overstimulation of either receptor may participate in Parkinson's disease. The unique ability of CNO to induce neuronal silencing in neurons that express hM 4 DREADD will facilitate studies aimed at investigating the role of defined neuronal populations in a large number of physiological and pathological processes.
Yeast Library Screen and Growth Assays. Plasmid library DNA was transformed into S. cerevisiae strain MPY578q5 (12) by a highefficiency procedure (30) and selected for growth at 30°C for 3-4 days in the presence 10 M clozapine, 1 M CNO, or Ϸ5 nM CNO for first-, second-, and third-generation libraries, respectively, on agar plates containing yeast assay buffer [synthetic complete (SC) media (pH 6.9) lacking uracil and histidine and supplemented with 20 mM 3-AT]. Colonies were then submitted to a secondary liquid-assay screen in which they were grown overnight in SC media without uracil, pelleted, washed with water, then diluted in yeast assay buffer to a final concentration of OD 650 Ϸ0.003. Diluted yeast (150 l) was added to a 96-well plate containing 50 l of yeast assay buffer supplemented with varying drug concentrations and grown with mild agitation at 25°C for 3 days, at which time the plate was read at OD 650 on a microplate reader by using SOFTmax Pro 4.3.1 software (Molecular Devices, Sunnyvale, CA). Plasmids were isolated from responsive colonies as described (31) and retransformed into MPY578q5 and/or sequenced. Pharmacological profiling of clones was performed by liquid assay by using two to three independent transformants and typically repeated two to six times. Viral Production, Cell Line Establishment, and Cell Culture. Human embryonic kidney strain, HEK T, was purchased from American Type Culture Collection (#CRL-11268; Manassas, VA), hPASMCs were purchased from ScienCell (San Diego, CA), and HEK strain 293TS cells were kindly provided by C. M. Counter (Duke University, Durham, NC). Amphotropic retrovirus was produced by cotransfecting a 6-cm plate of 293TS grown in DMEM/
